SOURCE: WayPoint Biomedical, Inc.

March 27, 2006 10:00 ET

WayPoint Biomedical Begins Their Global Drink Spiking Awareness Campaign in Canada This Week

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- March 27, 2006 -- WayPoint Biomedical, Inc. (OTC: WYPH) is launching their worldwide drink spiking public awareness campaign in Canada this week. Two different press conference events will be held; the first on March 28, 2006 in Toronto, Ontario, the second will be on the following day in Vancouver, British Columbia. In each location, WayPoint executives will conduct a press conference highlighting the global increase in drink spiking, followed by a street corner survey with America's Street Corner Pollster Chris Harris.

The survey is designed to find out how many women have been victims of drink spiking, or know of others who have had their drinks spiked. Harris will be asking women subjects, "Would you accept a drink from a stranger?" As Harris asks the opening question, a drink will be served to the woman subject. Five other questions pertinent to the issue will follow the opening question.

Over the past six months global incidents of drink spiking at bars, nightclubs, private parties, and on college campuses has risen to epidemic proportions. Community law enforcement and campus police are bewildered and frustrated about how to address the problem of drink spiking - a serious crime that often leads to other crimes, including: rape, robbery, poisoning and even murder. CBS4 Boston stated in a recent piece (February 6th, 2006) that incidents of Drink Spiking have risen dramatically from 14% in 2002 to 21% in 2005 - a 33% increase in less than 3 years!

In Canada, the Drink Detective™ drink spiking detection kit is now being sold at Procurity Pharmacies in Manitoba. In addition, such high street names as Pharmasave of British Columbia, Shopper's Drug Mart in Ontario, United Pharmacies in Saskatchewan, and Pharmaplus in Ontario all have listed the Drink Detective™ for future placement. With well over 1,000 combined store locations among the above chains, WayPoint projects Drink Detective sales to top half a million dollars by mid-year.

About WayPoint Biomedical, Inc.:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information